Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Hereditary Hemorrhagic Telangiectasia
NCT01314274Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2011
- Primary completion
- Jun 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hereditary hemorrhagic telangiectasia (HHT), epistaxis, sponsored by Medical University of Vienna. Started Mar 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxis
Beyond the preview
Go deeper on NCT01314274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01314274.